Sfoglia per AUTORE
MATTIELLO V
Collezione AOU Città della Salute di Torino

  

Items : 6

First-line treatment of Waldenström's macroglobulinemia in Italy: A multicenter real-life study on 547 patients to evaluate the long-term efficacy and tolerability of different chemoimmunotherapy strategies. in American journal of hematology / Am J Hematol. 2025 Jan;100(1):189-191. doi: 10.1002/ajh.27524. Epub 2024 Nov 19.

2025
AO Ordine Mauriziano
AOU Città della Salute di Torino

Piazza F; Frustaci AM; Hohaus S; Zamprogna G; Peri V; Noto A; Scapinello G; Musto P; Pasquale R; Petrilli D; Stirparo L; Fresa A; Innocenti I; Motta M; Rossini B; Bullo M; Marino D; Ferrarini I; Cencini E; Puccini B; Rizzi R; Olivieri J; Danesin N; Galli E; Mattiello V; Benevolo G; Tedeschi A; Autore F; Ferrero S; et alii...

Kinetics of lymphocytosis in naïve chronic lymphocytic leukemia patients treated with covalent Bruton's tyrosine kinase inhibitors: An Italian multicenter real-life experience. in HemaSphere / Hemasphere. 2024 Nov 28;8(12):e144. doi: 10.1002/hem3.144. eCollection 2024 Dec.

2024
AOU Città della Salute di Torino

Innocenti I; Mosca A; Tomasso A; Galitzia A; Scarfò L; Morelli F; Galli E; Martini F; Sangiorgi E; Laureana R; Benintende G; Mattiello V; Chiriu S; Del Principe MI; Zamprogna G; Gentile M; Martino EA; Cappello E; Montalbano MC; Farina G; Innao V; Stirparo L; Patti C; Sportoletti P; Fresa A; Catania G; Coscia M; Bellesi S; Tedeschi A; et alii...

Antibody Response to the SARS-CoV-2 Vaccine and COVID-19 Vulnerability during the Omicron Pandemic in Patients with CLL: Two-Year Follow-Up of a Multicenter Study. in Cancers / Cancers (Basel). 2023 May 30;15(11):2993. doi: 10.3390/cancers15112993.

2023
AOU Città della Salute di Torino

Mauro FR; Giannarelli D; Galluzzo CM; Visentin A; Frustaci AM; Sportoletti P; Vitale C; Reda G; Gentile M; Levato L; Murru R; Armiento D; Molinari MC; Proietti G; Pepe S; De Falco F; Mattiello V; Barabino L; Amici R; Coscia M; Tedeschi A; Girmenia C; Trentin L; Baroncelli S;

Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study. in Hematological oncology / Hematol Oncol. 2023 Dec;41(5):877-883. doi: 10.1002/hon.3199. Epub 2023 Jul 1.

2023
AOU Città della Salute di Torino
AOU Novara

Cuneo A; Foà R; Trentin L; Gattei V; Coscia M; Mattiello V; Rigolin GM; Gentile M; Moia R; Scortechini I; Sportoletti P; Catania G; Loseto G; Chiurazzi F; Malerba L; De Paolis MR; Angeletti I; Ferrari A; Giordano A; Baratè C; Quaresmini G; Farina L; Fresa A; Leone MMA; Piciocchi A; Vitale C; Visentin A; Reda G; Innocenti I; et alii...

High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study. in Haematologica / Haematologica. 2023 Aug 1;108(8):2091-2100. doi: 10.3324/haematol.2022.282116.

2023
AOU Alessandria
AO Cuneo
AO Ordine Mauriziano
AOU Città della Salute di Torino
AOU Novara

Foà R; Nanni M; Del Giudice I; Guarini A; Fazi P; Vignetti M; Piciocchi A; Cuneo A; Neri A; De Novi LA; De Propris MS; Pietrasanta D; Mattiello V; Visentin A; Vitale C; Albano F; Molinari MC; Liberati AM; Giordano A; Gottardi D; Galieni P; Patrizi VB; Tani M; Arcari A; Musuraca G; Deodato M; Massaia M; Rigolin GM; Scarfò L; et alii...

Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study. in Frontiers in oncology / Front Oncol. 2022 Nov 21;12:1033413. doi: 10.3389/fonc.2022.1033413. eCollection 2022.

2022
AOU Città della Salute di Torino

Laurenti L; Coscia M; Reda G; Scarfò L; Cellini A; Angotzi F; Pravato S; Marchetti M; Gozzetti A; Molica S; Murru R; Quaglia FM; Rigolin GM; Gentile M; Sportoletti P; Mattiello V; Cibien F; Vitale C; Sanna A; Fresa A; Mauro FR; Catania G; Visentin A; Ghia P; Foà R; Cuneo A; Trentin L;